JP2017524740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524740A5 JP2017524740A5 JP2017525320A JP2017525320A JP2017524740A5 JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5 JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017524740 A5 JP2017524740 A5 JP 2017524740A5
- Authority
- JP
- Japan
- Prior art keywords
- affinity matrix
- heterodimer
- range
- polypeptide
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 24
- 239000000833 heterodimer Substances 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000000872 buffer Substances 0.000 claims 7
- 239000000710 homodimer Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000003196 chaotropic effect Effects 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012539 chromatography resin Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000012433 multimodal chromatography Methods 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 claims 1
- 229940005991 chloric acid Drugs 0.000 claims 1
- 239000005289 controlled pore glass Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| US62/029,463 | 2014-07-26 | ||
| PCT/US2015/041936 WO2016018740A2 (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524740A JP2017524740A (ja) | 2017-08-31 |
| JP2017524740A5 true JP2017524740A5 (https=) | 2020-01-30 |
| JP6702967B2 JP6702967B2 (ja) | 2020-06-03 |
Family
ID=53836215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525320A Active JP6702967B2 (ja) | 2014-07-26 | 2015-07-24 | 二重特異性抗体のための精製プラットフォーム |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (https=) |
| EP (2) | EP3912987B9 (https=) |
| JP (1) | JP6702967B2 (https=) |
| KR (1) | KR102440737B1 (https=) |
| CN (1) | CN107074906B (https=) |
| AR (1) | AR101262A1 (https=) |
| AU (1) | AU2015298156B2 (https=) |
| DK (2) | DK3172221T3 (https=) |
| EA (1) | EA036154B1 (https=) |
| ES (2) | ES2942533T3 (https=) |
| FI (1) | FI3912987T3 (https=) |
| IL (1) | IL255198B (https=) |
| MX (1) | MX377558B (https=) |
| MY (1) | MY187051A (https=) |
| PL (2) | PL3172221T3 (https=) |
| SG (2) | SG11201700157VA (https=) |
| TW (1) | TWI704155B (https=) |
| WO (1) | WO2016018740A2 (https=) |
| ZA (1) | ZA201700622B (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| AU2008304748C1 (en) | 2007-09-26 | 2014-06-12 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| US10294306B2 (en) * | 2015-05-28 | 2019-05-21 | Bio-Rad Laboratories, Inc. | Affinity ligands and methods relating thereto |
| CN108368166B (zh) * | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | 提高含fc区多肽纯化效率的方法 |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| CN109563124A (zh) * | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | 多特异性抗体的纯化 |
| WO2018038469A1 (ko) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| CN111902720B (zh) | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| MX2021001915A (es) | 2018-08-17 | 2021-05-31 | Regeneron Pharma | Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica. |
| CN112839959A (zh) * | 2018-09-21 | 2021-05-25 | 特尼奥生物股份有限公司 | 用于纯化异源二聚多特异性抗体的方法 |
| JPWO2020066270A1 (ja) * | 2018-09-28 | 2021-08-30 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| ES2962578T3 (es) | 2018-10-31 | 2024-03-19 | Regeneron Pharma | Método y sistema de identificación y cuantificación de una proteína |
| BR112021005522A2 (pt) * | 2018-11-21 | 2021-06-29 | Regeneron Pharmaceuticals, Inc. | anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, métodos de prevenção, tratamento ou melhoria de infecção por s. aureus, uma condição causada por infecção por s. aureus, ou pelo menos um sintoma de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, uma condição causada por infecção por s. aureus, de pelo menos um sintoma de infecção por s. aureus, para prevenir uma infecção por s. aureus, de prevenção, tratamento ou melhoria de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, em um indivíduo com um cateter, uma articulação protética ou qualquer outro objeto estranho, para prevenir, tratar ou melhorar a infecção estafilocócica, ou para diminuir a frequência ou gravidade da infecção estafilócica |
| CN112996801A (zh) * | 2018-11-26 | 2021-06-18 | 北卡罗来纳州大学 | 用于捕获宿主细胞蛋白的肽配体 |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| IL284317B2 (en) | 2018-12-24 | 2025-10-01 | Sanofi Sa | Multispecific binding pseudo-fab proteins |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| SG11202112462RA (en) | 2019-06-11 | 2021-12-30 | Regeneron Pharma | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| MX2021015087A (es) * | 2019-06-13 | 2022-01-18 | Regeneron Pharma | Metodos para eliminar componentes no deseados durante procesos cromatograficos de multiples etapas. |
| US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| WO2021130717A1 (ko) * | 2019-12-26 | 2021-07-01 | 에이비엘바이오 주식회사 | 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법 |
| KR102834449B1 (ko) | 2019-12-27 | 2025-07-15 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| EP4281467A4 (en) * | 2021-01-25 | 2024-12-04 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| CN118414350A (zh) * | 2021-10-19 | 2024-07-30 | 阿特根公司 | 纯化具有igg fc结构域的融合蛋白的方法 |
| WO2023247468A2 (en) * | 2022-06-22 | 2023-12-28 | Puridify Limited | Kappa light chain-binding convection matrix |
| US20250076310A1 (en) | 2022-12-08 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
| WO2025073922A1 (en) * | 2023-10-04 | 2025-04-10 | Sartorius Bia Separations D.O.O. | Enhanced chromatographic separations of components in a mixture by employing chaotropic elution |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2025131519A1 (en) * | 2023-12-21 | 2025-06-26 | Cytiva Bioprocess R&D Ab | Antibody separation with a vh3 binding separation matrix |
| WO2025173342A1 (ja) * | 2024-02-13 | 2025-08-21 | Jsr株式会社 | Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法 |
| WO2026075981A1 (en) * | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Methods of analyzing heterodimeric proteins |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2169299T3 (es) | 1996-09-03 | 2002-07-01 | Gsf Forschungszentrum Umwelt | Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos. |
| ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| EP1115427B1 (de) | 1998-09-25 | 2003-12-03 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| TWI372763B (en) * | 2005-06-17 | 2012-09-21 | Wyeth Llc | Methods of purifying anti a beta antibodies |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CL2008000883A1 (es) | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| KR101856792B1 (ko) * | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| RS67768B1 (sr) * | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| PT2825559T (pt) * | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
| CA2886036A1 (en) * | 2012-09-25 | 2014-04-03 | Ichnos Sciences SA | Purification of hetero-dimeric immunoglobulins |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es active IP Right Grant
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/en active Active
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/en active Active
- 2015-07-24 MX MX2017001217A patent/MX377558B/es active IP Right Grant
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/en not_active Ceased
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active Active
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524740A5 (https=) | ||
| FI3912987T3 (fi) | Puhdistusalusta bispesifisille vasta-aineille | |
| JP2012515160A5 (https=) | ||
| Arrua et al. | Review of recent advances in the preparation of organic polymer monoliths for liquid chromatography of large molecules | |
| JP2014501758A5 (https=) | ||
| JP2014500311A5 (https=) | ||
| JP2016502843A5 (https=) | ||
| JP2018510867A5 (https=) | ||
| JP2017086090A5 (https=) | ||
| JP2019033754A5 (https=) | ||
| RU2017100005A (ru) | Способ очистки белка слияния | |
| JP2018023398A5 (https=) | ||
| JP2015512893A5 (https=) | ||
| JP2015537212A5 (https=) | ||
| JP2015227386A5 (https=) | ||
| JP2013530156A5 (https=) | ||
| Holstein et al. | Mobile phase modifier effects in multimodal cation exchange chromatography | |
| JP2012522736A5 (https=) | ||
| Pezzini et al. | A comprehensive evaluation of mixed mode interactions of HEA and PPA HyperCel™ chromatographic media | |
| TWI660774B (zh) | 吸附材料 | |
| Wang et al. | Evaluation of mixed-mode chromatographic resins for separating IgG from serum albumin containing feedstock | |
| JP2011500757A5 (https=) | ||
| Nian et al. | Void exclusion of antibodies by grafted-ligand porous particle anion exchangers | |
| Arrua et al. | Monolithic cryopolymers with embedded nanoparticles. II. Capillary liquid chromatography of proteins using charged embedded nanoparticles | |
| JP2015518489A5 (https=) |